@article{00e9cb85ed514473af6f4e4c56217aef,
title = "Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: Protocol for an overview of systematic reviews",
abstract = "Introduction:With the increasing availability of cannabis and cannabinoids and their potential utility for pain treatment, there is a growing need to evaluate the risk-benefit considerations of cannabinoids for the management of pain. As part of the IASP Cannabis and Cannabinoids Task Force, this protocol describes a planned overview of systematic reviews summarizing the risks of harm with cannabinoids that are relevant to patients receiving pain treatment.Methods:This overview will involve literature searches of several databases and a defined search strategy that will target systematic reviews or meta-analyses of cannabinoids where harms are the primary focus. Data extraction will include various features of the cannabinoid(s) and the harm(s) being studied as well as other methodological features of each included systematic review. Methodological quality of each included review will be assessed using AMSTAR-2 as well as compliance with the PRISMA harms checklist. Prospero registration pending.Discussion:The broad overview of reviews defined by this protocol is expected to synthesize available good quality evidence of harms that will help inform risk-benefit considerations about the use of cannabinoids for pain management.",
keywords = "Adverse effects, Adverse events, Cannabinoids, Cannabis, Clinical trials, Harms, Pain management",
author = "Ian Gilron and Blyth, {Fiona M.} and Louisa Degenhardt and {Di Forti}, Marta and Christopher Eccleston and Simon Haroutounian and Andrew Moore and Rice, {Andrew S.C.} and Mark Wallace",
note = "Funding Information: I. Gilron is a co-principal investigator of the CIHR SPOR Canadian Pain Network (CPN). I. Gilron has received industry support from Adynxx, Biogen, Eupraxia, Novaremed, and Teva. I. Gilron is cochair of the Clinical Research Network of the CPN, which receives research support from Canopy Health, Toronto Poly Clinic, and CannTrust. L. Degenhardt has received untied educational grants from Reckitt Benckiser, Indivior, Munipharma, and Seqirus for the conduct of postmarketing surveillance studies of opioid medications. M. Di Forti reports grants from MRC and personal fees from Janssen, outside the submitted work. S. Haroutounian has received research support from Pfizer Inc (ASPIRE neuropathic pain grant program) and industry support from Medoc Ltd. A. Moore reports personal fees from Novartis and personal fees from RB, outside the submitted work. A.S.C. Rice reports other from International Association for Study of Pain, during the conduct of the study; personal fees from Imperial College Consultants; and other from Spinifex/Novartis, outside the Funding Information: This work was supported, in part, by the Queen{\textquoteright}s University Department of Anesthesiology & Perioperative Medicine, and the Chronic Pain Network of the Canadian Institutes of Health Research Strategy on Patient-Oriented Research. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = may,
day = "1",
doi = "10.1097/PR9.0000000000000742",
language = "English",
volume = "4",
journal = "Pain Reports",
issn = "2471-2531",
number = "3",
}